Search for Associate Director for Clinical Research and Holden Chair
Page content transcription
If your browser does not render page correctly, please read the page content below
ABOUT THIS POSITION 1 CHANGING MEDICINE. CHANGING LIVES. Search for Associate Director for Clinical Research and Holden Chair
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 2 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
ABOUT THIS POSITION 3 CHANGING MEDICINE. CHANGING LIVES. Contents About this search.........................................4 Holden Comprehensive Cancer Center...............................................9 History....................................................................10 Today......................................................................14 Holden Family Support.....................................16 Organization and Leadership.........................18 Research Programs........................................... 22 Cores and Shared Resources......................... 29 University of Iowa Health Care.............45 UI Carver College of Medicine..............59 UI Hospitals and Clinics..........................75 Health Sciences Campus....................... 85 University of Iowa..................................... 91 The Iowa City Community....................97
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 4 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH About this Position The Holden Comprehensive Cancer Center (HCCC) at The University of Iowa is seeking an outstanding clinician- investigator to serve as the associate director for clinical research and to direct the Roland W. Holden Family Program in Experimental Therapeutics. The successful candidate will also serve as the Holden Family Chair. As the associate director for clinical research The ideal candidate will also have familiarity of an NCI-designated Comprehensive Cancer with both laboratory and clinical aspects of Center Center, the successful candidate will be cancer experimental therapeutics and drug expected to provide leadership and integrate development, investigator-initiated and all therapeutically related translational and cooperative group clinical trials, knowledge clinical cancer research taking place within the of regulatory guidelines and procedures, and institution, and also contribute to establishing familiarity with NCI-designated Cancer Center external collaborations. The successful operations. candidate will have an MD or MD/PhD degree, with a strong record of publication and funding, The successful candidate will have their including external peer-reviewed funding, in primary academic appointment in a clinical clinical cancer research and experimental department at The University of Iowa Carver therapeutics. Experience in a multi-disciplinary College of Medicine. A leadership role in the setting, experience in program development Division of Hematology, Oncology, and Blood in an academic medical center, commitment and Marrow Transplantation in the Department to diversity in the workplace, and excellent of Internal Medicine is available based on the communication and leadership skills are interest and qualification of the applicant. required.
ABOUT THIS POSITION 5 CHANGING MEDICINE. CHANGING LIVES. The HCCC received NCI-designation In addition, a number of cancer type in 1999 and comprehensive specific muliti-disciplinary oncology designation from the NCI in 2000. groups (MOGs) have been developed It has undergone successful and are active in both clinical and competitive renewal of this research efforts. The HCCC has a designation twice since that time. robust Clinical Trials Support Core The HCCC is organized in two that includes 35 full-time staff who different dimensions. The formal assist in protocol development, research programs of the HCCC are management, and the conduct of based on scientific discipline and trials. The Clinical Trials Support include cancer immunology and Core also supports bedside to bench immunotherapy, cancer signaling and translational research including experimental therapeutics, cancer the prospective clinical registries of genetics and gell growth, tumor the HCCC. These are known as the imaging, free radical cancer biology, Molecular Epidemiology Resources and cancer epidemiology. (MERs), work closely to the HCCC Tissue Procurement Core and biobanks, and have enrolled over 4,500 subjects in a variety of cancer types.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 6 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH Role and Responsibilities The Holden Comprehensive Cancer Center associate director for clinical research will lead the clinical and translational research efforts of the cancer center. This includes providing administrative oversight of the clinical research infrastructure, clinical research collaborative efforts, clinical and translational research pilot grant programs, serving as a mentor to junior investigators and determining use of funds dedicated to clinical cancer research. The associate director will serve on the HCCC Leadership Committee and Research Executive Committee, and will chair the Clinical Research Leadership Committee. The associate director for clinical research will supervise the assistant directors for clinical research. Together, they will oversee the Clinical Trials Support Core, Clinical Trials Development, Support and Monitoring Office, Protocol Review Committee and the Data and Safety Monitoring Committee as well as the 12 cancer-specific multidisciplinary oncology groups.
ABOUT THIS POSITION 7 CHANGING MEDICINE. CHANGING LIVES. Endowed Positions and Programs The Holden Endowment to support Experimental Therapeutics was established in 2000 to support research geared towards advancing knowledge of cancer and application of this knowledge to the discovery and development of new cancer therapeutics. This research is expected to include the design and synthesis of novel chemicals and testing of active agents in humans. The endowment consists of two components.: Holden Family Chair This fund supports a chair in the University of Iowa Roy J. and Lucille A. Carver College of Medicine for the Director of the Roland W. Holden Family Program for Experimental Cancer Therapeutics. Roland W. Holden Family Program for Experimental Cancer Therapeutics The Program itself is supported by the Roland W. Holden Family Endowed Fund. Support for the clinical research infrastructure of the Holden Comprehensive Cancer Center comes from other sources so support from the Roland W. Holden Family Program for Experimental Cancer Therapeutics can be directed towards specific research projects in Experimental Cancer Therapeutics. Dr. Raymond Hohl was the founding Director of the Program. Dr. Hohl’s efforts focused on the RAS pathway and novel approaches to targeting the isoprene intermediates in the cholesterol biosynthetic pathway. His efforts included extensive collaborations with synthetic chemists in the Department of Chemistry as well as a broad range of investigators across the Cancer Center. The next recipient of the Holden Chair will be expected to leverage the infrastructure and contributions developed by Dr. Hohl while also applying their own research expertise to goals of the Holden Program in Experimental Therapeutics.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 8 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH Search Committee K A RL W. T H O M A S , M D GA RY ROS EN T HA L , MD Chair Director, Iowa Institute for Clinical and Executive Vice Chair, Department of Internal Translational Science Medicine Professor of Internal Medicine Professor of Internal Medicine firstname.lastname@example.org email@example.com MO H A M M E D M . M I L H E M , M B BS YAT IN V YA S , MD, PHD Deputy Director for Clinical Cancer Care, Director, Division of Pediatric Hematology and Holden Comprehensive Cancer Center Oncology Associate Professor of Internal Medicine Professor of Pediatrics firstname.lastname@example.org email@example.com K I M B E RLY K . L E S L I E , M D JA MES C. WA L K ER, PHD Chair and Department Executive Officer, Associate Vice President for Research Department of Obstetrics and Gynecology firstname.lastname@example.org email@example.com MI C H A E L H E N RY, P H D B RIA N K . L IN K , MD Deputy Director for Research, Holden Director, Clinical Trials Support Core, Holden Comprehensive Cancer Center Comprehensive Cancer Center Associate Professor of Molecular Physiology Professor of Internal Medicine and Biophysics firstname.lastname@example.org email@example.com ALIASGER SALEM, PHD PA LOMA H. G IA N GRA N DE , PHD Lyle and Sharon Bighley Professor of Associate Professor of Internal Medicine Pharmaceutical Sciences and Leader, Cell Signaling and Experimental Therapeutics firstname.lastname@example.org Program, Holden Comprehensive Cancer Center email@example.com
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 10 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH Holden Comprehensive Cancer Center Efforts to form a comprehensively organized program in cancer began in the 1970s when former Dean John W. Eckstein, MD charged the College of Medicine’s Committee on Cancer with the responsibility of reviewing and developing research, demonstration, and education programs in cancer. Richard L. DeGowin, MD began the effort by Since 1980, the Cancer Center has experienced working with faculty members in the College’s tremendous growth and achieved the highest of Medicine, Nursing, Dentistry, Pharmacy level of recognition status given by the National and Liberal Arts and Sciences and after much Cancer Institute—comprehensive—in work, a plan was implemented for the creation 2000. To reflect this achievement, and in of a more organized cancer program at the recognition of a landmark, $25 million gift university. Following presentation to the from four generations of the Holden family of Board of Regents, State of Iowa, in 1980 the Williamsburg, Iowa, the Cancer Center was new program was conferred special “center renamed the Holden Comprehensive Cancer designation, ” and DeGowin became the Cancer Center. Center’s first director.
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER 11 CHANGING MEDICINE. CHANGING LIVES.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 12 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH Timeline 1980 The University of Iowa cancer program is conferred special “center” status by the Iowa Board of Regents. Richard L. DeGowin named director. 1981 1998 George J. Weiner, MD, appointed The Cancer Center received a three-year CancerCenter director of the Cancer Center. Support Grant from the National Cancer Institute. 1993 The grant was not renewed. With the support of a generous gift from the Pappajohn family of Des Moines, the John and Mary Pappajohn Clinical Cancer Center opened, providing a multidisciplinary approach to state-of-the-art patient care. This effort was coordinated by Richard D. Williams, MD. 1988 University of Iowa, University of Iowa College of Medicine and 1995 1986 University of Iowa Hospitals and Clinics leadership develop plans University of Iowa for expanded laboratory research President Mary Sue Cancer Information initiatives and construction of new Service opens. Coleman, PhD, College clinical care facilities. of Medicine Dean Robert Kelch, MD and R. Edward Howell, director and 1994 CEO of the UI Hospitals and Clinics—all recently appointed—reinforce The NCI provided funds for restructuring the Cancer institutional commitments Center through a P20 Cancer Center Planning Grant. to support and strengthen This effort was led by Richard G. Lynch, MD. the Cancer Center. Robert B. Wallace, MD, was appointed as director of the Cancer Center.
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER 13 CHANGING MEDICINE. CHANGING LIVES. 1999 The Cancer Center submitted a Cancer 2002 Center Support Completion of the new Roland 2007 2011 2014 Grant application and Ruby Holden New image guided NCI- Dr, Raymond Hohl, to the Cancer Research center for radiation designation as a associate director National Laboratories. therapy opens. comprehensive for clinical research Cancer cancer center and Holden Chair, Institute. Iowa receives its Renewal of $11.9 following moves to Penn State first Specialized million Specialized competitive University as director Program of Research Program of review with of the Penn State Excellence (SPORE) Excellence (SPORE) a score of Hershey Cancer Grant—the Iowa/ grant for lymphoma “outstanding.” Center. Mayo Lymphoma research. SPORE. 2001 2008 Center receives National Outstanding Achievement Award from the Commission on Cancer for providing superior care to patients and Construction families. begins on the Holden Center Iowa teams up with several agencies to provide housing, Cancer Research Laboratories 2005 transportation and medical assistance to cancer patients devastated by the floods and tornadoes in Iowa. in the new NCI-designation as a Medical comprehensive cancer center Education renewed following competitive and Research review. Facility. 2004 Iowa Consortium for Comprehensive Cancer Control launched, providing coordinated cancer control for Iowans. 2000 The National Cancer Institute conducts a site visit of the Cancer Center in January. The National Cancer Institute confers “NCI-designated Cancer Center” status in July. The Cancer center receives a landmark, $25 million gift from four generations of the Holden family of Williamsburg, Iowa and is renamed Holden Cancer Center. The Roland W. Holden Family Program for Experimental Therapeutics was established and Dr. Raymond Hohl, was named the Roland W. Holden Family Chair for Experimental Cancer Therapeutics. Holden Cancer Center achieves the highest level of recognition—comprehensive status given by the National Cancer Institute and is renamed Holden Comprehensive Cancer Center.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 14 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH The Center Today Holden Comprehensive Cancer • Free Radical and Cancer Biology Center remains dedicated to bringing • Tumor Imaging While research is conducted in world-class research and cancer care laboratories throughout the University to Iowa, the Midwest, and beyond. • Cancer Epidemiology of Iowa campus, the Roland and Ruby • Cancer Genomics and Cell Growth Holden Cancer Research Laboratories The matrix center now spans the allow the Center to integrate many University of Iowa and includes Each of these programs is focused on researchers in close proximity to each approximately 180 formal Cancer a cancer-relevant scientific discipline, other. Center members and many additional is translational, and includes physicians, investigators and other members from several colleges and Outreach to the people of Iowa is staff from 36 related university diverse backgrounds. an important component of the departments and six colleges, as well Center’s activities. Holden provides as the University of Iowa Hospitals The Holden Comprehensive information through its Cancer and Clinics and the University of Iowa Cancer Center is also organized Information Service to patients, their Children’s Hospital. based on cancer type through the families, and health professionals. Multidisciplinary Oncology Groups In addition, there are a number of Research at Holden Comprehensive (MOGs). The MOGs are responsible cancer support groups that meet Cancer Centeris organized into six for coordinating multidisciplinary regularly in local communities. The research programs: clinical care through tumor boards, Center also includes many patients • Cancer Immunology and multidisciplinary clinics, etc. in its active program of Phase I and Immunotherapy They also serve as the focus for Phase II clinical trials. development of innovative clinical • Cancer Signaling and Experimental trials. Therapeutics
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER 15 CHANGING MEDICINE. CHANGING LIVES. Holden Comprehensive Cancer Center Statistics C LI N I C AL AC T I V I T Y C L I N ICA L FACIL IT IES A N D S PACE RES EA RCH A N D S PACE 154,232 37 $74.2 Total visits to UI Health Care with Exam rooms in Million in total annual cancer-related primary diagnosis of cancer the Cancer Clinic research funding 31,372 3 $44 Unique patients treated with Consult rooms in Million in current endowments in primary diagnosis of cancer the Cancer Clinic support of the mission 48,288 2 221 Total visits in the Treatment Rooms in Open clinical trials for cancer clinic the Cancer Clinic cancer patients 3,615 32 3,289 Admissions for patients with a Chairs in the Patients enrolled in primary diagnosis of cancer chemotherapy suite clinical trials 3,800 8 189 New cancer patients diagnosed Beds in the Cancer Center members in 36 at UI Hospitals and Clinics chemotherapy suite departments and six colleges 20,400 >146,000 6 Radiation oncology Net square feet of Research Programs treatments delivered clinical oncology space in the Center 14,639 74 10 Chemotherapy sessions Inpatient beds on three units Core Facilities supported by the delivered with a dedicated pharmacy Cancer Center 117 14 4 Bone marrow transplants Beds in the Adult Leukemia and Core Facilities supported by the (106 adult, 11 pediatric) Bone Marrow Transplant Unit Lymphoma SPORE grant 8,283 31 33,953 Contacts to the Cancer Bone bone marrow transplant and Square feet of research space in Information Service hematology oncology beds Holden Research Laboratories
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 16 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH Holden Family Support Through years of visionary support for the Holden RES EA RCH Comprehensive Cancer Center at the University of Iowa, Cutting-edge research, new cancer investigators, and the Holden family has helped establish the UI as a major studies that have translated laboratory discoveries into center for cancer research, patient care, and education. innovative patient treatment options. The Holden Comprehensive Cancer Center was so named in 2000, when four generations of the Holden family made The Clinical Trials Support Core, which include trials a landmark gift of $25 million to support what was then the that come from our own labs, collaboration with other University of Iowa Cancer Center. In the 13 years since the cancer centers, and partnerships with biotechnology and Holden gift, world-class research scientists, physicians, pharmaceutical companies. Treatments that would not and other health care professionals have worked tirelessly otherwise be available in Iowa are available to our patients to advance research that helps prevent, detect, and treat because of these trials. cancer for our patients. PAT IEN T S ERV ICES A N D CA RE The Holden family gift was made in honor of the late Roland W. Holden, who died in 1995. Holden founded The UI Palliative Care Service—a team of nurses, social Holden Foundation Seeds Inc., a corn seed research and workers, chaplains and physicians that assists terminally ill genetics company based in Williamsburg, Iowa, 30 miles patients and their families. This interdisciplinary program west of Iowa City, in 1937. His family chose to celebrate his provides emotional and spiritual support and help in legacy by supporting research and treatment that may planning for care outside the hospital, as well as pain eventually cure the disease that took his life. control and symptom management. Contributors to the $25 million gift included Ruby Holden; Ronald, Arlene, and Kathy Holden; Susan and David McCurry; Karol Holden; Mary Ann and Curtis Blythe; and the Roland and Ruby Holden Foundation. The gift, one of the largest received for UI Health Care initiatives, has supported a full range of critical programs within the Holden Comprehensive Cancer Center, including:
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER 17 CHANGING MEDICINE. CHANGING LIVES. The Holden family of Williamsburg, Iowa.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 18 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH HCCC Executive Board Jean Robillard, MD Vice President for Medical Affairs Organization Director George Weiner, MD Deputy Director for Research Michael Henry, PhD Executive Director of Development Internal and External Sarah Russett, UI Foundation Advisory Boards Associate Director for Clinical Research Assistant Director for Assistant Director for Clinical Multidisciplinary Clinical Research Research Services Mohammed Milhem, MBBS Daniel Vaena, MD Carlie Etscheidt (Administrative Director) Multidisciplinary Multidisciplinary Clinical Trials Oncology Groups Oncology Group Protocol Review and Support Core Research Support Carmen Tilman Coordinator Monitoring Brian Link, MD (Board Coordinator) Julianna Kennedy (Director) Protocol Clinical Trials Clinical Trials Development and DSM Chair Data Management Clinical Trials Informatics Support Regulatory Manager Translational Systems Specialist Monitoring Chair Daniel Berg, MD Manager Research Manager Michael Goodheart, MD Mary Schall Marian Andersen Inez Mattke Laura Jacobus Protocol Clinical Research Regulatory Associate Translational Research Specialists T. Kriegel Assistants Development and M. Arnold (90%) C. Hamlin Monitoring Manager R. Arthur Financial Analyst A. Janoski Gary Rick M. Frees B. Franzwa T. Knutson J. Geick Miller J. Gallagher M. Brumm Protocol Writer and K. Parrott S. Rosazza Safety Officer J. Wegmann Cancer and Leukemia M. Rosenquist P. Zehr Group B Coordinator Biospecimen Collection C. Halvorsen Technician Protocol Management Clinical Research J. Cook-Granroth Assistant Associates National Surgical A. Childs S. Gillen Adjuvant Breast Data Manager J. Schlabaugh and Bowel Project S. Grimm (temp) Coordinator Clinical Research C. Robertson Assistants J. de la Garza Clerk III S. Teahen L. Johnson (75%) Clinical and Data Management Research Specialist A. Tricot Data Managers A. Marlof A. Schultz A. Capper A. Ulin Medical Assistant II J. Larson
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER 19 CHANGING MEDICINE. CHANGING LIVES. Leadership George J. Weiner, MD Director, Holden Comprehensive Cancer Center George Weiner MD, is an active translational cancer investigator who has been on the faculty at the University of Iowa since 1989. He is Director of the Holden Comprehensive Cancer Center (HCCC), Professor of Internal Medicine, C.E. Block Chair of Cancer Research, and a faculty member in the Interdisciplinary Program in Immunology at the University of Iowa. Administratively, Dr. Weiner was appointed Director of the HCCC on December 1, 1998, and led the HCCC to recognition as an NCI-designated comprehensive cancer center in 2000. This designation was renewed in 2005 and 2011. Dr. Weiner was served in a number of leadership positions at the state and national level including the following. • Chair, NCI subcommittee A also known as the Cancer Center Parent Committee (2007- 2009). He chaired site visits for the NCI at 8 cancer centers. • Vice President / President Elect, Association of American Cancer Institutes (2013-present). • President, Iowa Cancer Consortium (2003-present) • Chair, Governmental Affairs Committee, American Society of Hematology (2008-2012) • Co-Chair, Science Policy and Governmental Affairs Committee, American Association for Cancer Research (2012-present) • Chair of External Advisory Boards for 3 NCI designated cancer centers. • PI of the Iowa/Mayo Lymphoma SPORE (2002-present) • Co-Chair, C-Change initiative on Comprehensive Cancer Control • Member, CTAC - NCI Clinical and Translational Research Advisory Committee (2012-present) Dr. Weiner’s research focuses on understanding the mechanisms of action of anti-cancer monoclonal antibodies, and on development of novel approaches to immunotherapy of lymphoma. He has been continually funded by the NCI since 1991. Dr. Weiner’s research extends from basic laboratory investigation to clinical trials. He is the holder of four patents with a number of others pending, and was the first to demonstrate Toll Like Receptor 9 agonists could be used successfully as immune adjuvants in tumor immunization. He also has made major contributions to our understanding of the mechanisms of action responsible for the anti-tumor activity of monoclonal antibodies.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 20 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH GAI L A . BI SHOP, P H D E L I Z A B E TH CHRIS CHIL L ES , PHD MICHA EL D. HEN RY, PHD Associate Director for Basic Research Associate Director for Population Science Deputy Director for Research Dr. Gail Bishop, appointed associate Elizabeth Chrischilles, the Marvin A. Dr. Henry serves as deputy director director for basic research in 2004, and Rose Lee Pomerantz Chair in for research. This important position advises the HCCC director on Public Health, and director, Health is supported by institutional funds. issues related to the basic science Effectiveness Research Center, was He has focused his efforts on new programs, including allocation of appointed as the HCCC associate initiatives and special projects research space, and resources, director for population sciences in including developing the overall and membership in the research 2007. Molecular Oncology Initiative. A programs. Bishop’s role is to major focus of this effort is improving coordinate and assure the quality of In this role, Dr. Chrischilles is tissue collection, annotation and the basic science research programs charged with enhancing the HCCC’s distribution through the Tissue of the Center, to provide advice on population science activities including Procurement Core/Biospecimens faculty recruitment in basic science epidemiology, prevention, community Initiative including identification of a areas, formulate program policy, and health, public policy and outcomes software package described above. overseeing the use of basic science analysis. She provides leadership to He has also worked on integrating shared facilities in consultation with the research programs considered the molecular pathology group the associate director for research primarily population science into the HCCC. This has included infrastructure. Bishop works with programs and provides advice and promoting meetings of the director the HCCC director to encourage guidance to HCCC members relative of the Molecular Pathology Division, translation of basic advances to to population science activities Dr. Aaron Bossler, with MOGs and the clinic. As associate director for within the HCCC. She also has medical oncologists to assess basic science, Dr. Bishop reviews all the responsibility of encouraging ongoing needs for new actionable applications for HCCC membership. population science activities in the molecular tests. In late 2013, the She is a member of both the HCCC other research programs. molecular pathology group received Executive Committee and Associate CLIA certification for sequencing Director’s Committee. The research Dr. Chrischilles is a member of the capabilities of 50 cancer-related programs that are primarily focused HCCC Executive Committee and the genes that are now being used on basic cancer research (Cancer Associate Directors Committee. for both clinical care and clinical Genomics and Cell Growth, and research. Dr. Henry also chairs Free Radical Cancer Biology) report the monthly Research Executive formally to her. Dr. Bishop also Committee meeting which includes provides advice related to the basic all of the Program Leaders and Co- laboratory research taking place in Leaders. the other four research programs.
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER 21 CHANGING MEDICINE. CHANGING LIVES. DAVI D M . LU B A RO F F, P H D M O HA MMED M. MIL HEM, MD CHRIS TOPHER L AUB EN T H AL , MBA Associate Director for Research Infrastructure Deputy Director for Clinical Cancer Services Associate Director for Administration David Lubaroff, Ph.D., has served Dr. Milhem has been a faculty The associate director for as associate director for research member at the University of Iowa, administration, plans, directs, and infrastructure since 1998. In his role, and a member of the Holden coordinates, the administrative he is responsible for coordinating Comprehensive Cancer Center since operations and activities of the HCCC the shared research resources and 2007. including both research and clinical working closely with the directors activities. Laubenthal facilitates of these facilities to assure they are He has a remarkable record of interactions with the UI Hospitals serving the needs of HCCC members. accomplishments related to clinical and Clinics and the Carver College He serves on the faculty advisory research team leadership in that of Medicine to enhance clinical and committees of the majority of shared period of time, and is an emerging basic research productivity. He serves research resources supported leader in the field of clinical cancer as liaison with other departments, by the HCCC. He also monitors research both institutionally and colleges, and outside organizations. usage of shared research resources nationally. He works closely with senior and makes recommendations to leadership to assure coordination and the shared resource resources Dr. Milhem is deputy director for communication related to cancer based on their performance. Dr. clinical cancer services in hte Holden oriented clinical service, research Lubaroff explores the need for and Comprehensive Cancer Center. In and education. He manages all fiscal development of new shared research this role he leads the development activities, including coordination of resources by periodically surveying of better clinical services to help the annual budget process (operating HCCC membership to document cancer center achieve its goals and to and capital), analysis of income shared facility activities and unmet facilitate clinical cancer research and and expenditures, projections for needs. His responsibilities include activities. He is leading many efforts annual budget requests, fiscal developing, coordinating and to improve workflow for clinician reports, equipment and supplies, maintaining research educational researchers and improve processes. maintenance, and assisting with and programs for members including overseeing the grants management seminars and conferences, and a process. He is administratively program of visiting research scientists responsible for the administration and lecturers. He coordinates the of the grant application process and monthly HCCC Forum. Lubaroff works the conduct of research activities in closely with HCCC administrative the HCCC including oversight of the staff in oversight of shared research shared core resources. This includes resource activities. Dr. Lubaroff is approximately $54.7 million in direct a member of the HCCC Executive costs of which approximately 14.4 Committee and Associate Directors million is managed directly by the Committee Cancer Center.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 22 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH Research Programs Cancer Immunology and Immunotherapy AB OUT TH E P ROGRA M L EA DERS HIP The Cancer Immunology and Immunotherapy Program consists of faculty investigators who are linked by common research interests in the functioning of the immune system, and how that system can be manipulated to help prevent or treat cancer and complications of cancer. The investigators in this program are working on problems that extend from fundamental molecular questions to those involving how recent advances in basic immunology can be translated into clinical utility for the treatment of cancer. ZUHAIR K. GAIL A. BALLAS, MD BISHOP, PHD Professor of Internal Professor of Although many of investigators in the Cancer Immunology and Medicine Microbiology and Immunotherapy Program are pursuing related questions, the individual Internal Medicine research programs are diverse, allowing researchers in this program to attack basic biologic issues, and develop new clinical therapies, from many angles. Model systems being studied range from an evaluation of signaling properties of T and B cells, to increasing the efficacy of vaccines and immunotherapy in living animals, through the conduct of novel clinical trials related to cancer immunotherapy. Clinical applications, as a direct result of more basic investigations, have arisen from within the group and it is expected that this will continue. Because of the diversity of research interests reflected within the membership of the Cancer Immunology and Immunotherapy Program, a wide range of technologies and approaches are available to investigators. Each of our investigators benefits from interactions with others in the program, as well as members of additional Cancer Center programs, resulting in a synergism yielding new insights, perspectives, and collaborative efforts.
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER 23 CHANGING MEDICINE. CHANGING LIVES. Cancer Signaling and Experimental Therapeutics Program ABOUT THE P RO G RA M L EA DERS HIP The overall organizational goal of the Cancer Signaling and Experimental Therapeutics Program is to facilitate the application of recent advances in our understanding of cell signaling, cell cycle control, and apoptosis, to the development of new pharmacologic approaches to cancer prevention and therapy. Investigators in this program are working on problems that extend from ALIASGER K. YATIN M. fundamental molecular questions involving signaling pathways to those SALEM, PHD VYAS, MD involving the design of novel compounds based on our growing knowledge of Associate Professor Professor of of Pharmaceutics Pediatrics molecular aspects of cell biology. Such laboratory scientists collaborate with other members of the Program who are clinical investigators with a broad range of backgrounds and expertise in performing innovative clinical cancer trials. The program includes basic and clinical investigators from multiple departments at the University of Iowa, and has members who have primary appointments in the Colleges of Medicine, Pharmacy, and Liberal Arts. Kimberly Leslie, MD at work in her laboratory.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 24 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH Tumor Imaging Program AB OUT TH E P ROGRA M L EA DERS HIP The goal of the Imaging Program is to foster interdisciplinary research that integrates modern medical imaging techniques into basic, translational, and clinical cancer research studies. The methodologies will include computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, positron emission tomography (PET), gamma scintigraphy, optical imaging, and autoradiography. Metabolic imaging extends the capability of imaging well beyond anatomy. It includes imaging blood flow, vascular permeability, MICHAEL JOHN metabolic rates (glucose, oxygen, DNA synthesis, protein synthesis, membrane GRAHAM, MD, BUATTI, MD PHD Professor and Chair, synthesis), receptor distribution and density (estrogen, testosterone, Professor of Radiation Oncology somatostatin), apoptosis, angiogenesis, cell trafficking, and reporter gene Radiology activation. Members of the imaging program are working in all these areas. The importance of having an Imaging Program is that it brings these investigators together to collaborate, and share ideas, imaging strategies, and data analysis methods. The Imaging Program has the following specific areas of focus: • Metabolic assessment of response to therapy • Iodine symporter as a reporter gene and as a novel therapy • Cell trafficking • Development of new radiopharmaceuticals • Development of novel analysis methodologies Eric Hoffman, MD works with students and staff in the Magnetic Resonance Research Facility.
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER 25 CHANGING MEDICINE. CHANGING LIVES. Free Radical and Cancer Biology Program ABOUT TH E P RO G RA M L EA DERS HIP For many years it has been recognized that many agents used to treat cancer (i.e., radiation and chemotherapy agents) cause oxidative stress that contributes to the mechanism by which they kill cancer cells as well as damage normal tissues. Recently, it is becoming increasingly clear that metabolic oxidation/reduction (redox) reactions are also altered in cancer vs. normal cells. The current consensus is that cancer cells may exist in a chronic state of metabolic oxidative stress that may represent a significant underlying DOUGLAS R. FREDERICK E. mechanism contributing to malignancy. A unifying goal of the investigators SPITZ, PHD DOMANN, JR., Professor of PHD in the Free Radical Cancer Biology Program is to utilize a comprehensive Radiation Oncology Professor of understanding of redox biology to develop novel biochemical rationales Radiation Oncology for improving cancer therapy taking advantage fundamental differences in oxidative metabolism between cancer vs. normal cells. The researchers in the Free Radical Cancer Biology Program (FRCBP) focus on studying the biological consequences of inherent differences in redox metabolism between cancer vs. normal cells to determine the role that redox reactions play in cancer phenotypic changes relevant to cell growth, differentiation, signal transduction, metastasis, functional molecular imaging, and cancer therapy. A unifying goal of the program is to utilize a comprehensive basic science understanding of cancer cell redox biology to develop novel biochemical rationales for improving cancer therapy. Three overlapping themes exist within the program. Theme 1 Theme 2 Theme 3 Understanding the role of redox Understanding the role of redox Exploring the role of oxidative stress biochemistry in regulation of genetic regulation in cell biology. Within this in cancer therapy outcomes. Within and epigenetic gene expression theme are focus groups exploring this theme are focus groups exploring pathways relevant to cancer biology. the effects of intracellular redox the role of manipulating oxidative Within this theme are focus groups environmental changes on the stress to improve cancer therapy exploring redox and gene expression cell cycle, and on invasion and as well as using imaging of oxidative globally, as well as gene expression metastasis. metabolism as an approach to of key redox molecules such as monitor and guide therapy. glutathione, thioredoxin, SOD, and AP2.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 26 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH Cancer Epidemiology Program AB OUT TH E P ROGRA M L EA DERS HIP The overall goal of the Cancer Epidemiology Program is to save lives by increasing our understanding of what causes cancer, promoting cancer prevention behaviors and early detection and treatment, and developing improved diagnostic tests and treatments. When cancer cannot be prevented, we are also interested in research that will extend the quantity and quality of life for the cancer survivor. CHARLES F. LYNCH, MD, PHD A major strength of the Cancer Professor of Epidemiology and Pathology Epidemiology Program is its extension beyond the walls of the medical center, as its primary research population is residents across the state of Iowa. This is based on the role played by the University of Iowa in public health across Iowa, including Barcey Levy, MD, PhD cancer epidemiology. Members of the Cancer Epidemiology Program are responsible for the State Health Registry of Iowa (SHRI), Iowa’s statewide cancer surveillance program that is part of the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (NCI). This resource allows researchers in the Cancer Epidemiology Program to perform outstanding population-based cancer research. Information gained from these studies can then be applied to other states and other populations. The Cancer Epidemiology Program has three focus areas. • Cancer Etiology • Cancer Health Services and Outcomes • Cancer Prevention and Control
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER 27 CHANGING MEDICINE. CHANGING LIVES. Cancer Genomics and Cell Growth Program ABOUT TH E P RO G RA M L EA DERS HIP Research in the Cancer Genomics and Cell Growth Program focuses on genetic and molecular events controlling normal versus malignant cell proliferation, differentiation and survival. The overall goal of the program is to define biologically significant genetic and molecular alterations in tumor cells so that information can be used to more effectively detect and treat human cancers. There are two major overlapping themes within the umbrella of the Progam’s research. DAWN E. SIEGFRIED QUELLE, PHD JANZ, MD, DSC Associate Professor Professor of Theme 1 of Pharmacology Pathology Genomic organization and cancer gene expression/analysis Theme 2 Cell growth, differentiation, survival and transformation. Major accomplishments of the Cancer Genomics and Cell Growth Program over the past funding period are best reflected by its identification and characterization of novel cancer genes and/or biomarkers, development of novel animal tumor models to discover and assess cancer gene function in vivo, and increasing collaboration as demonstrated by coalescence of program members into effective working groups. Key examples of intraprogrammatic research collaborations include a) studies revealing the role of chromatin binding proteins (such as RPA, DNA polymerases, HP1, transcription factors) in gene expression and how that impacts the cancer phenotype, b) studies defining basic mechanisms of viral infection and replication, and how that leads to cell transformation, and c) the discovery and subsequent functional analysis of novel genetic pathways of carcinogenesis. There are numerous past and present productive collaborations both between members of the Program, and with members of other Cancer Center programs. There are currently 16 NIH and NCI funded projects involving multiple Program members and/or HCCC members from other programs serving as co-Investigators. The program consists of 36 members from 12 departments (8 basic science and 4 clinical departments) and 5 Colleges. Peer-reviewed, research funding for this program totals $8,449,398 with $2,583,657 coming from the NCI. Members of the Program have 300 cancer-related publications with nearly 30% collaborative publications (17% intra-programmatic, 12% inter- programmatic) during the last grant period.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 28 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER 29 CHANGING MEDICINE. CHANGING LIVES. Core Facilities and Shared Resources The Holden Comprehensive Cancer Center provides Center members with access to the services and resources of our core facilities. The facilities provide quality products and services that enhance the research efforts of Cancer Center investigators to foster basic and translational research. Members of the Cancer Center with peer-reviewed, funded projects are the primary beneficiaries of these core resources. The core facilities within the Holden Comprehensive Cancer Center are funded by a combination of funding from the Cancer Center Support Grant, Institutional support, other University of Iowa sources and charge-back for services. David Lubaroff, PhD, associate director for research infrastructure oversees these cores. Clinical Trials Support Core • Clinical Trials Data • Clinical Trials Translational • Clinical Trials Regulatory • Protocol Development and Monitoring Cancer Center Support Grant • Clinical Trials Support Core • Gene Transfer Vector Core • Bioinformatics Core • High Throughput Screening Core • Biostatistics Core • Population Research Core • Central Microscopy Research Facility • Radiation and Free Radical Research Core • DNA Core • Small Animal Imaging • Flow Cytometry Core • Tissue Procurement Core Lymphoma SPORE Grant Other Resources • Biospecimens • Molecular Pathology Resource • Biostatistics and Bioinformatics • Proteomics Resource • Clinical Research • Drug Discovery Resources
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 30 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH Clinical Trials Support Core PUR P OSE S E RV I C E S L EA DERS HIP The Clinical Trials Support Core • Routing of protocols through the University of Iowa (CTSC) provides administrative Institutional Review Board or Western Institutional services and data management Review Board and the appropriate regulatory to all members of the Holden committees Comprehensive Cancer Center who • Providing expertise in coordination of clinical trial conduct clinical studies.The CTSC is activities (recruitment of patients, determining BRIAN K. LINK, a shared resources and is designed eligibility, obtaining consent, scheduling procedures, MD to facilitate the conduct of high- Director coordinating patient care needs, managing data quality clinical and translational collection) cancer research and is composed • Serving as liaison to pharmaceutical companies, of dedicated staff with expertise in governmental regulatory agencies and other outside protocol management and study vendors coordination. • Budget writing and billing • Assisting investigators with annual reviews, protocol modifications and reporting of adverse events • Providing assistance with collection and processing blood and tissue samples for translational research • Listing of all current clinical trials in the clinical trials booklet The Holden Comprehensive Cancer Center is also an active participant of seven National Cooperative Groups and investigators within the Center enroll over 550 patients on clinical research studies each year. The National Cooperative Group Trials that are involved within the Holden Comprehensive Cancer Center include: • Cancer and Acute Leukemia Group B (ALLIANCE) • National Surgical Adjuvant Breast Project (NSABP) • Eastern Cooperative Oncology Group (ECOG) • Collaborative Ocular Melanoma Study (COMS) • Children’s Oncology Group (COG) • Gynecological Oncology Group (GOG) • Radiation Therapy Oncology Group (RTOG) The Clinical Trials Support Core is currently staffed by approximately 32 staff members.
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER 31 CHANGING MEDICINE. CHANGING LIVES. Bioinformatics Core PUR POS E S E RV ICES L EA DERSH IP To provide bioinformatics support for Assistance is available on all types of projects, ranging Cancer Center investigators in the from clinical trials to basic science experiments. Early design, data collection/archiving and consultation during the design of a study may be analysis of high-throughput genomics especially beneficial. assays in cancer research projects. • Consultation on study design, selection of technology platforms and formulation of hypotheses THOMAS L. CASAVANT, PHD • Specification of appropriate software tools and Director methods for data analysis • Database creation (DNA sequence, RNA expression, proteomics, etc.) • Protocol development • Information technology consultation • Data and experiment analysis • Assistance in preparation of manuscripts • Education and training Biostatistics Core PUR POS E S E RV ICES L EA DERSH IP To provide statistical support for Assistance is available on all types of projects, ranging Cancer Center investigators in the from clinical trials to basic science experiments. Early design, analysis, and reporting of consultation during the design of a study may be cancer research projects. especially beneficial. • Consultation on study design, selection of outcome variables and formulation of hypotheses BRIAN J. SMITH, • Specification of appropriate methods of data analysis PHD Director • Protocol development • Generation of randomization schedules • Data analysis • Assistance in preparation of manuscripts • Education and training.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 32 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH Central Microscopy Research Facility PUR POS E S E RV I C E S L EA DERS HIP The Central Microscopy Research • Scanning electron microscopy Facility provides instrumentation • Transmission electron microscopy and technical assistance to research programs involving the use of • Light microscopy scanning and transmission electron • Laser capture microdissection microscopy, light and confocal • Confocal microscopy RANDY A. microscopy, scanning probe NESSLER, BGS, microscopy, freeze fracture and x-ray • Multi-photon microscopy MBA Director microanalysis. • Cryo-techniques • Elemental analysis • Atomic force microscopy • Bioluminescence microscopy The facility also provides all solutions, supplies and training necessary for investigators involving microtomy including: • Specialized staining and embedding techniques • Negative staining • Metal coating • Autoradiography • Cryo-fixation • Cryomicrotomy • Enzyme-cytochemistry • Immunocytochemistry • Morphometry Scanning electron microscopy. • Stereology
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER 33 CHANGING MEDICINE. CHANGING LIVES. DNA Core PUR POS E S E RV ICES L EA DERSH IP The purpose of the DNA Facility is • DNA Microarrays (Affymetrix GeneChip system and to provide a centralized resource for Custom DNA microarrays using slide format) access to state-of-the-art equipment • Real-time PCR used in DNA sequence and transcript analysis. The DNA Facility strives to • DNA Sequencing (Sanger dideoxy sequencing using provide high quality services with capillary-based instruments and genomic sequencing KEVIN rapid turnaround and support their using the Roches 454 and ABI SOLID instruments KNUDTSON, PHD services with well trained personnel Director • Synthetic Oligonucleotide that are able to consult with users • Molecular biology computing including custom on how they may best utilize their nucleic acid analysis, microarray analysis and genomic services. The DNA Facility continues sequence assembly/analysis. to evaluate and update their services so they remain cutting-edge, and • Bioanalyzer to assess nucleic acid quality and quantity provide new services as necessary to continue to meet the needs of Center investigators. Kevin Knudtson, PhD gives a tour of the core during a STEM education program.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 34 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH Flow Cytometry Core PU R POS E S E RV I C E S L EA DERS HIP The Flow Cytometry Core is located In addition to identification and isolation of various cell in the Eckstein Medical Research populations using antibodies, flow cytometry can analyze: Building (EMRB). The facility has one • Cell proliferation response to drugs or treatments, such magnetic-based and six laser-based as those used in chemotherapy instruments whose major purpose is the identification and isolation of • Cell physiological properties, such as calcium flux and pH ZUHAIR K. various cell populations. The laser- BALLAS, MD based instruments accomplish • DNA content and integrity Director this by the use of antibodies to • Transfection markers such as GFP and mCherry which various colors or dyes have been attached and are directed at Offline data analysis using FlowJoTM, CellquestTM, and molecules known to exist on the ModFITTM can be done through the facility’s system of cell surface. By using several colors networked computers. Investigators equipped with IBM attached to different antibodies, or Mac-compatible PCs can perform analysis at their one can identify and purify cells that laboratories or offices by accessing data through the express any given configuration of Facility’s dedicated 1.5 terabyte file server. various molecules. The facility provides scientific and technical personnel who are available for consultation in designing experimental protocols. Cell preparation protocols and publication quality output are available upon request. A student is trained on instrumentation in the core.
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER 35 CHANGING MEDICINE. CHANGING LIVES. Gene Transfer Vector Core PUR POS E S E RV ICES L EA DERSH IP The Gene Vector Core assists The University of Iowa Carver College of Medicine GTVC researchers interested in developing brings together investigators interested in developing and and using viral vector construction. using, viral and non-viral vectors for gene transfer with The core utilizes molecular biology specialists in the area of vector construction by: techniques to engineer and produce • Consultation with the principal investigator to plan viral and non-viral vectors in and develop transfer vectors to fit individual projects BEVERLY L. quantities necessary for gene transfer requirements DAVIDSON, PHD in research experiments or preclinical Director studies. Core staff works closely with • Assist investigators with troubleshooting existing investigators to plan and develop projects gene transfer vectors to fit individual • Design and development of novel vectors project requirements. • Develop novel methods of virus production such as the RapAdTM System for adenovirus production • Generation of RNAi expression vectors • Purify, concentrate, and perform quality control on preparations of recombinant adenovirus, adeno- associated virus (AAV), moloney murine retrovirus, lentivirus, baculovirus, and vaccinia virus • Maintain and distribute standard cell lines and stocks of recombinant reporter viruses
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER 36 SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH High Throughput Screening Core PUR POS E S E RV I C E S L EA DERS H IP Initiated by the Vice President A robotic platform is available with 8-independent for Research and the Holden channels and a 384 channel pipetting head. A liquid Comprehensive Cancer Center handling robot is also equipped with on-board incubators through collaboration with multiple (4 plates) and two positions for incubation/chilling of departments, and housed in stock solutions. the College of Pharmacy, the MENG WU, PHD High Throughput Screening, An integrated Perkin Elmer Envision Multimode high Director Target Validation and Biomarker speed plate readed for use with detection is equipped Identification Resource is aimed at with filters and monochromators. The plate reader, pharmacologic characterization of controlled through the integrated software, supports new molecular entities in enzyme, fluorescence, time-resolved flouorescence, fluorescence receptor and cell-based systems, polarization, time-resolved FRET, absorbance and including potency, intrinsic activity, specialized screening technologies including AlphaScreen, selectivity, specificity, and off-target DELFIA and LANCE. The Envision is also equipped with effects. This activity also includes two photomultipliers and a dedicated uHTS laster for high the identification and validation/ speed AlphaScreen. qualification of biomarkers for target activation/inhibition, proof- The laboratory is also equipped with a five-color Roche of-concept, efficacy and safety. An Lightcycler 480 II system, allowing for secondary example is the use of high throughput confirmation of hits binding to a purified target using screening for the discovery of novel differential scanning fluorimtetry. pre-therapeutic lead molecules directed at neurological applications. Two small molecular libraries are currently available. The Strong leadership and multiple pilot Spectrum Library consists of 2,320 structurally diverse grants have led to a large number of compounds including marketed and experimental drugs collaboration exploratory projects in and natural products. A larger collection houses 50,000 the very short time that the center small molecules representing a wide swath of chemical has been functional. space, optimized to be “drug-like.” Management of compound library plates and screening data is done through M-Screen, a web-accessed academic database for analysis and curation.
You can also read